Abstract
Much attention has been focused on transcutaneous immunization strategies to stimulate systemic cytotoxic T lymphocyte responses leading to anti-tumor or anti-microbial immunity. Here we report that topical application of vaccines consisting of synthetic peptides formulated with imiquimod, a Toll-like receptor agonist that functions as a potent adjuvant generates strong T cell responses that exhibit effective anti-tumor effects in a murine melanoma model system. These results support the use of peptide-based transcutaneous vaccines as a noninvasive and effective strategy for anti-tumor immunotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 430-437 |
Number of pages | 8 |
Journal | Journal of Immunotherapy |
Volume | 28 |
Issue number | 5 |
DOIs | |
State | Published - 2005 |
Externally published | Yes |
Keywords
- Animal model
- Cutaneous vaccine
- Melanoma
- Toll-like receptor adjuvant
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pharmacology
- Cancer Research